FSD Pharma Inc. currently owns 85,003,750 shares of Canarra Biotech, which plans to be the largest indoor cultivation facility in Quebec and recently purchased a modern 625,000 sq. ft. facility on 27 acres of land, located less than one hour drive from Montreal. FSD Pharma and Cannara have a further agreement in place where FV Pharma will lease over 105,000 square feet of Cannara’s facility for the purpose of cultivating and/or selling cannabis and cannabis-derived products. At this time, FSD Pharma and Cannara Biotech have a combined floor space of over 1.245 million square feet of indoor growing capacity.
Tel Aviv, Israel
FSD Pharma Inc. shall receive premium access to the cannabinoid scientific research platform developed by SciCann in Israel, which includes a network of leading researchers, academic institutions and medical centers. This platform will enable FSD Pharma to execute a series of rigorous clinical studies for cannabis-based products in a highly time and cost-efficient environment, to fulfil its stated goal of becoming the global leader in the new emerging field of clinically proven cannabinoid-based therapies.
Alberta + Saskatchewan
A fully integrated retail distribution company that has applied for 31 retail cannabis permits in Alberta and 16 in Saskatchewan, with application expected to be submitted for British Columbia shortly. The company owns four of Canada’s most prominent retail brands that are poised to take advantage of the legal recreational market in Canada which is anticipated to be enacted into law in fall of 2018.
Collaboration and Profit Sharing Agreement
Canntab Therapeutics was founded on April 20, 2016 by pharmaceutical industry professionals who saw an urgent need to add industry rigour and professionalism to the medicinal cannabis market. We are the first company solely dedicated to the research and development of oral dosage therapeutic formulations of cannabis. We started by developing unique, patent pending technology which has resulted in the creation of a range of oral dosage products that effectively treat different ailments by delivering a uniform dosage of medicinal cannabis extract. Each is available in different dosage levels, available in instant and stable extended release.
Collaboration and License Agreement
World Class was incorporated under the Business Corporations Act (Ontario) on January 25, 2018 as a private company. World Class has developed a unique extraction process to produce quality, potent cannabis extracts. The extraction technology (the “WCE Technology”) uses ultrasound to effectively produce extracts from cannabis and hemp and isolate essential compounds found in plant material. The WCE Technology has a number of advantages over conventional extraction methods, including the ability to: (i) produce higher concentrated compounds; (ii) process larger volumes of cannabis or hemp; (iii) utilize undried cannabis or hemp in the process; (iv) utilize all parts of the cannabis or hemp plants, and, (v) reduce production time.
Collaborative Research Agreement
FSD has signed a LOI with Solarvest to develop and test pharma-grade cannabinoids out of algae. The Pharma Grade process could reduce the production time for targeted cannabinoid molecule(s) by up to 95%. Solarvest is an algae technology company whose production platform provides it with an extremely flexible system capable of being adapted to produce numerous products. The Company has completed a feasibility study for the expression of CBD and THC as a way to produce cannabinoids in sterile GMP facilities.
First Republic Capital focuses on public Canadian and US micro-cap companies. Clients receive more than just financing – they get a dedicated investment banking partner with the responsiveness, credibility and capability to help them achieve their market goals. First Capital partners with their clients and supports them over time as their business and capital structure evolves and provides aftermarket support.
Collaboration and Profit-Sharing Agreement
FSD has signed a collaboration and profit-sharing agreement with Pharmastrip for the production and delivery of organic medical cannabis infused in oral thin film strips. Pharmastrip has granted FSD an exclusive, perpetual license to manufacture and sell the oral thin film strips in Canada. Pharmastrip proprietary equipment will be installed at the FSD facility in Cobourg.
FSD completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide. As part of the investment, Huge Shops has the option to acquire a minimum of ten retail locations under Chairman’s umbrella of properties, and, subject to availability and further negotiation, purchase additional Coffee Time sites.